Literature DB >> 33416421

Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy.

Alexis Genthon1, Thibault Chiarabini2, Pierre Baylac2, Nadia Valin2, Tomas Urbina3, Jérome Pacanowski2, Arsène Mekinian4, Eolia Brissot1, Fella M 'Hammedi-Bouzina1, Simona Lapusan1, Mohamad Mohty1, Karine Lacombe5, Patrick Ingiliz2.   

Abstract

Entities:  

Year:  2021        PMID： 33416421     DOI： 10.1080/10428194.2020.1869963

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor.

Authors:  Bruno Fattizzo; Juri Alessandro Giannotta; Nicola Cecchi; Wilma Barcellini
Journal:  Am J Hematol       Date:  2021-06-18       Impact factor: 13.265

2.  COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.

Authors:  Ana Maria Cabal-Herrera; Farrah J Mateen
Journal:  J Neurol       Date:  2021-04-27       Impact factor: 6.682

3.  COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: A case report.

Authors:  Juraj Sokol; Frantisek Nehaj; Michal Mokan; Lenka Lisa; Jan Stasko
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 4.  Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.

Authors:  Bruno Fattizzo; Raffaella Pasquale; Valentina Bellani; Wilma Barcellini; Austin G Kulasekararaj
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

Review 5.  Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.

Authors:  Panagiota Gianni; Mark Goldin; Sam Ngu; Stefanos Zafeiropoulos; Georgios Geropoulos; Dimitrios Giannis
Journal:  World J Exp Med       Date:  2022-07-20

Review 6.  Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.

Authors:  Waqar Waheed; Eric Newman; Marwa Aboukhatwa; Maryam Moin; Rup Tandan
Journal:  Ther Clin Risk Manag       Date:  2022-07-12       Impact factor: 2.755
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.